mor00208
Showing 1 - 2 of 2
Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Prolymphocytic Leukemia Trial
Active, not recruiting
- Contiguous Stage II Small Lymphocytic Lymphoma
- +11 more
- MOR00208
- +2 more
-
Columbus, OhioThe Ohio State University Comprehensive Cancer Center
Feb 24, 2022
Diffuse Large B-cell Lymphoma Trial in Worldwide (MOR00208, Lenalidomide)
Active, not recruiting
- Diffuse Large B-cell Lymphoma
- MOR00208
- Lenalidomide
-
Bakersfield, California
- +52 more
Sep 1, 2021